Oral Anticoagulant Therapy for Atrial Fibrillation Decreases Dementia Risk
A study was conducted to determine the effect of oral anticoagulant therapy on risk for dementia in patients with nonvalvular atrial fibrillation.
Diagnosis & Disease Information
Subclinical Valvular Heart Disease Increasingly Common Among Older Adults
Researchers sought to describe the prevalence of VHD stages among older adults; determine the prognostic relevance of VHD stages for incidence CVDs; and characterize the progression in VHD stages over 6 years in late life.
Ablation vs Pharmacotherapy: Quality of Life for Women With Atrial Fibrillation
Researchers sought to compare quality of life outcomes between ablation and pharmacotherapy in women with atrial fibrillation.
Amplatzer Amulet Approved to Reduce Thromboembolic Risk in Atrial Fibrillation
The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology.
Apixaban Tied to Lower Risk of Gastrointestinal Bleeding
Findings were consistent for patients aged 80 years or older and patients with chronic kidney disease, who are often underrepresented in clinical trials.
New-Onset SVT Following Colonoscopy Bowel Prep Explored in Case Series
A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.
OAC in Patients With AF and COVID-19 Lowers Rates of Death, Thrombotic Events
Researchers assessed the relationship between oral anticoagulation for patients with COVID-19 and AF and incidence of in-hospital thrombotic events and death.
Early VT Ablation Does Not Associate With Reduced Mortality in Patients With an ICD
A study was conducted to determine the efficacy of treating patients with ICDs and ventricular tachycardia with early catheter ablation.
A Quarter of Patients With Implantable Electronic Devices Have Subclinical AF
A study was conducted to determine the epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices.
NDA Submitted for Landiolol, a Highly Cardioselective Beta-Blocker
Landiolol is an ultra-short acting, cardioselective, beta-1 adrenoceptor blocker designed to reduce heart rate with a minimal effect over cardiac contractility.
- Loading...
Loading...
Next post in Cardiology
Loading... 
Loading...